Replies

A summary of expected effects after COVID vaccination is in Figure 1.

Figure 1: Summary of cardiovascular events following COVID vaccination

Discussion

The pathways discussed herein are inevitable routes of spike protein transit in the body and in the cells. ACE2 receptors are abundant in every known cell type. When spike proteins have been introduced to the body, either through the SARS-CoV-2 virus or by means of the mRNA COVID vaccines, is there any realistic way possible to block their interaction with ACE2 receptors in any individual? In the case of acute infection with SARS-CoV-2, infected individuals have a self-limiting encounter with spike proteins, which may be thwarted by some of the therapeutics mentioned above. However, in the case of the mRNA-vaccinated, no endpoint of spike protein production is yet known. Nor is it yet known if it is safe to use any of the spike protein blocking therapeutics in vaccinated individuals.

In the absence of extraordinary and deliberate measures to block ACE2 receptors and CD147 receptors and/or Caspase 3/7 activity, is it then possible to expect that cardiac pericytes and endothelial cells could escape the pro-inflammatory and pro-apoptotic effects of the spike protein, especially considering that protein’s perpetual regeneration in vaccinated people? Could a therapeutic be invented for vaccinated people to protect their cardiomyocytes and pericytes from spike protein damage, and to be dosed frequently enough to combat the body’s ongoing spike protein production? If such an expectation is not realistic, then mRNA vaccines that prepare human cells to generate an unknown supply of spike proteins for an unknown amount of time are to be treated with extreme caution and avoidance until better understood. It is also necessary to defer further vaccination until there are known methods of both discharge of such proteins and the mechanism to turn off or attenuate mRNA-induced spike proteins, and/or to safely thwart the destructive effects of spike proteins in host cells.

We must also urgently learn the answer to the following question: Is the human recipient of a spike protein-generating mRNA vaccine reasonably expected to continue to generate spike proteins for an indefinite amount of time? Or even permanently? We need to know this, because the spike protein has been shown to have deleterious effects, and because myocarditis, which seems to be one of those effects, is now being observed in some vaccinated individuals, the mechanisms of which are discussed in this paper. There is observed precedent for mRNA medical treatments to have lasting effect on DNA, [44] which impacts future as well as present generations. Questions involving such serious potential consequences for human health must be answered, and standards of safety and informed consent must be met, before an ambitious and experimental procedure on the massive scale we are witnessing is deployed on populations. As a result, vaccines of this type must be avoided until these questions are thoroughly resolved, in order to prevent further harm to human health.

[1] US Centers for Disease Control (CDC). Clinical considerations: Myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. May 28 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html

To All Readers:

There are a total of Forty-Four studies cited at the article.
Here are the first seven:

[2] S Mouch, A Roguin, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine. Jun 29 2021. 39 (29). 3790-3793. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162819/

[3] J Su, M McNeil, et al. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. Vaccine. Jan 29 2021. 39 (5): 839-845. https://pubmed.ncbi.nlm.nih.gov/33422381/

[4] A Lala, K Johnson, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. Aug 4 2020. 76 (5). 533-546. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279721/

[5] A Chapman, A Shah, et al. Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury. Circulation. Mar 20 2018. 137 (12). 1236-1245. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882250/

[6] H Yamakawa, M Ieda. Cardiac regeneration by direct reprogramming in this decade and beyond. Inflamm, Regen. Jul 1 2021. 41 (20). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247073/

[7] S Mouch, A Roguin, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine. Jun 29 2021. 39 (29). 3790-3793. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162819/